Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Down 4.8%

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) dropped 4.8% on Monday . The stock traded as low as $13.94 and last traded at $14.07. Approximately 264,403 shares changed hands during mid-day trading, a decline of 71% from the average daily volume of 910,576 shares. The stock had previously closed at $14.78.

Analyst Upgrades and Downgrades

DAWN has been the topic of several research analyst reports. Piper Sandler reissued an “overweight” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Monday, July 8th. Wedbush reissued an “outperform” rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, July 25th. Bank of America raised Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and boosted their price objective for the stock from $11.00 to $24.00 in a research report on Thursday, August 1st. Needham & Company LLC reissued a “buy” rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Tuesday, July 30th. Finally, HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, August 1st. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $35.71.

Day One Biopharmaceuticals Trading Down 3.2 %

The business has a 50-day moving average price of $14.26 and a 200 day moving average price of $14.52. The stock has a market cap of $1.25 billion, a PE ratio of -5.74 and a beta of -1.51.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings results on Tuesday, July 30th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.70. The firm had revenue of $8.19 million for the quarter, compared to analysts’ expectations of $0.90 million. On average, equities analysts predict that Day One Biopharmaceuticals, Inc. will post -1.68 earnings per share for the current year.

Insider Activity at Day One Biopharmaceuticals

In related news, insider Samuel C. Blackman sold 30,000 shares of the business’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $14.22, for a total transaction of $426,600.00. Following the sale, the insider now directly owns 1,097,535 shares in the company, valued at approximately $15,606,947.70. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, insider Samuel C. Blackman sold 20,000 shares of the business’s stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $16.01, for a total transaction of $320,200.00. Following the sale, the insider now directly owns 1,121,081 shares in the company, valued at approximately $17,948,506.81. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Samuel C. Blackman sold 30,000 shares of the business’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $14.22, for a total value of $426,600.00. Following the sale, the insider now owns 1,097,535 shares in the company, valued at $15,606,947.70. The disclosure for this sale can be found here. In the last three months, insiders have sold 68,748 shares of company stock worth $1,009,272. 8.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Day One Biopharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in DAWN. Quest Partners LLC bought a new position in Day One Biopharmaceuticals in the 4th quarter worth about $29,000. Quintet Private Bank Europe S.A. increased its stake in Day One Biopharmaceuticals by 43.2% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after acquiring an additional 1,000 shares during the last quarter. SG Americas Securities LLC bought a new position in Day One Biopharmaceuticals in the 2nd quarter worth about $113,000. Point72 DIFC Ltd bought a new position in Day One Biopharmaceuticals in the 2nd quarter worth about $124,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in Day One Biopharmaceuticals in the 4th quarter worth about $156,000. 87.95% of the stock is currently owned by institutional investors.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.